Literature DB >> 19112730

Progress in the treatment of myelodysplastic syndromes.

Alice Maniatis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19112730      PMCID： PMC2626906          DOI： 10.2450/2008.0044-08

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  11 in total

1.  A limited number of 5-azacitidine cycles can be effective treatment in MDS.

Authors:  Catharina Müller-Thomas; Tibor Schuster; Christian Peschel; Katharina S Götze
Journal:  Ann Hematol       Date:  2008-08-12       Impact factor: 3.673

2.  Hypoxic erythrocytes spark lung leukocyte adhesion.

Authors:  Guy A Zimmerman
Journal:  Blood       Date:  2008-05-15       Impact factor: 22.113

3.  Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.

Authors:  P Maslak; S Chanel; L H Camacho; S Soignet; P P Pandolfi; I Guernah; R Warrell; S Nimer
Journal:  Leukemia       Date:  2006-02       Impact factor: 11.528

4.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Authors:  Andrea Pellagatti; Martin Jädersten; Ann-Mari Forsblom; Helen Cattan; Birger Christensson; Emma K Emanuelsson; Mats Merup; Lars Nilsson; Jan Samuelsson; Birgitta Sander; James S Wainscoat; Jacqueline Boultwood; Eva Hellström-Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

Review 5.  Chronic myelomonocytic leukemia: myeloproliferative variant.

Authors:  Francesco Onida; Miloslav Beran
Journal:  Curr Hematol Rep       Date:  2004-05

6.  Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.

Authors:  Hagop Kantarjian; Susan O'Brien; Farhad Ravandi; Jorge Cortes; Jianqin Shan; John M Bennett; Alan List; Pierre Fenaux; Guillermo Sanz; Jean-Pierre Issa; Emil J Freireich; Guillermo Garcia-Manero
Journal:  Cancer       Date:  2008-09-15       Impact factor: 6.860

Review 7.  Advances in the treatment of acute myeloid leukemia: from chromosomal aberrations to biologically targeted therapy.

Authors:  Michael Lübbert; Carsten Müller-Tidow; Wolf-Karsten Hofmann; H Phillip Koeffler
Journal:  J Cell Biochem       Date:  2008-08-15       Impact factor: 4.429

8.  A pilot pharmacokinetic study of oral azacitidine.

Authors:  G Garcia-Manero; M L Stoltz; M R Ward; H Kantarjian; S Sharma
Journal:  Leukemia       Date:  2008-06-12       Impact factor: 11.528

9.  International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.

Authors:  Jelena M Kao; Alex McMillan; Peter L Greenberg
Journal:  Am J Hematol       Date:  2008-10       Impact factor: 10.047

10.  Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.

Authors:  Martin Jädersten; Luca Malcovati; Ingunn Dybedal; Matteo Giovanni Della Porta; Rosangela Invernizzi; Scott M Montgomery; Cristiana Pascutto; Anna Porwit; Mario Cazzola; Eva Hellström-Lindberg
Journal:  J Clin Oncol       Date:  2008-06-16       Impact factor: 44.544
View more
  1 in total

1.  Cytogenetic features in primary myelodysplastic syndrome Egyptian patients.

Authors:  Yasser Elnahass; Lamiaa Youssif
Journal:  J Adv Res       Date:  2018-02-07       Impact factor: 10.479
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.